Correlation between anti-human leukocyte antigen antibodies and the outcomes of matched sibling donor transplantation in patients with hematological diseases
10.3760/cma.j.cn115356-20200330-00081
- VernacularTitle:血液病患者抗人类白细胞抗原抗体与同胞全相合造血干细胞移植预后的关系
- Author:
Leqing CAO
1
;
Siqi LI
;
Lanping XU
;
Xiaohui ZHANG
;
Yuhong CHEN
;
Huan CHEN
;
Wei HAN
;
Chenhua YAN
;
Yao CHEN
;
Yuanyuan ZHANG
;
Jingzhi WANG
;
Xiaodong MO
;
Tingting HAN
;
Yanru MA
;
Meng LYU
;
Kaiyan LIU
;
Xiaojun HUANG
;
Yingjun CHANG
Author Information
1. 北京大学人民医院 北京大学血液病研究所 国家血液系统疾病临床医学研究中心 造血干细胞移植治疗血液病北京市重点实验室 100044
- From:
Journal of Leukemia & Lymphoma
2020;29(8):453-457
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the relationship between anti-human leukocyte antigen (HLA) antibodies and transplant outcomes in patients with hematological diseases who underwent matched sibling donor transplantation (MSDT).Methods:A retrospective analysis was conducted in 168 patients with hematological diseases who received MSDT in Peking University People's Hospital from March 2015 to November 2017. All patients received detection of anti-HLA antibodies before transplantation, and the correlation between anti-HLA antibodies and transplant outcomes such as hematopoietic cells implantation, blood product transfusion and prognosis after transplantation were analyzed.Results:Among the 168 patients, 28 (16.7%) were positive for anti-HLA class Ⅰ or class Ⅱ antibodies, and 14 (8.3%) were positive for both anti-HLA class Ⅰ and class Ⅱ antibodies. All patients received neutrophil engraftment, 164 patients (97.9%) received platelet engraftment. Univariate analysis showed that there were no effects of anti-HLA antibodies on neutrophil engraftment and engraftment time, platelet engraftment and engraftment time, the volume of red cell transfusion, the volume of platelet transfusion, overall survival (OS) rate, disease free survival (DFS) rate and transplant-related mortality (TRM) in patients with hematological diseases underwent MSDT (all P > 0.05). Multivariate analysis showed that platelet engraftment was associated with better OS ( HR=0.065, 95% CI 0.017-0.252, P < 0.01), better DFS ( HR=0.083, 95% CI 0.024-0.289, P < 0.01) and lower TRM ( HR=0.094, 95% CI 0.014-0.626, P=0.015). Conclusion:Anti-HLA antibodies have no effect on transplant outcomes of patients with hematological diseases who have received MSDT.
